Developer of a disposable multifunctional catheter for effective
treatment of PPH (Post Partum Hemmorage).
Overview
MEDIVUR (formerly MEDEVICE) is an Israeli medical device start-up
Click here to request more information, about this company (FOR COLLABORATION IN R&D. ONLY!)
Note - you have to be registered in this server to
request information. If you haven't done so
yet, please register in this server
Your requests will be forwarded to the developer, who
will contact you directly
You can also see the list of
documents you already requested more information about
company, which operates under the framework of Migdal HaEmek
Technological Incubator as of April 1, 2007. Company's goal is to
develop a disposable multifunctional catheter for effective
treatment of PPH (Post Partum Hemmorage), bleeding following the
BPH (Bening Prostatic Hyperplasia) surgery and blood stoppage in
arteries during vascular procedures.
The technology is based on creating a negative pressure between
the balloons of the multifunctional catheter, inserted into
various hollow organs in the body, for creation of secure and
leak-proof fixation. The catheter also allows drug delivery into
operation zone.
Initially MEDIVUR will concentrate on development of the blood
occlusion catheter to be used instead of regular vascular clamps.
In ~10% of vascular surgeries (more that 1M procedures are
performed in US annually) the regular clamps can not be used
because of excessive calcification of the blood vessel, trauma to
the blood vessel wall, too deep location of the vessel and its
short length. In these cases Medevice Catheter can provide a
simple and effective solution making the surgery feasible. The
catheter is expected to be very competitive in this market
segment because of its leak-proof and secure connection also in
smooth lumen of the blood vessels.
Additional target market segment is the post-operative treatment
following BPH surgery. According to HCUP (Health care US project)
over 90,000 such procedures are performed in US annually. The use
of MEDIVUR's catheter for this application is expected to shorten
the hospitalization time, to reduce the need for catheter
replacement and rinsing and the number of blood transfusions
required during the post-operative treatment. This market segment
was chosen to be the first for Medevice catheter because of
easier regulatory requirements and shorter time to market.
